Friday, July 31

Browsing: LITESPARK012

Treatments

LITESPARK-012 Trial Does Not Meet Primary End Point for Advanced RCC Group

By NewsCancerApril 21, 20260

An investigational combination evaluating pembrolizumab (Keytruda), lenvatinib (Lenvima), and belzutifan (Welireg) did not meet the coprimary end points of progression-free…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

Browsing: LITESPARK012

LITESPARK-012 Trial Does Not Meet Primary End Point for Advanced RCC Group

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

CAR T-Cell Therapy Could Soon Expand Into Non-Oncology Indications

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

CAR T-Cell Therapy Could Soon Expand Into Non-Oncology Indications

Latest Post

OTUD6A promotes de novo pyrimidine synthesis by deubiquitinating and stabilizing CAD in cervical cancer

Atezolizumab Plus Chemotherapy Improves PFS in dMMR/MSI-H Metastatic CRC

FDA Advisory Committee Backs RP1/Nivolumab for Advanced Melanoma

Subscribe to Updates

What's Hot

Browsing: LITESPARK012